Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

TRPV1 as a novel therapeutic target in type 2 diabetes mellitus

Aug. 19, 2019

Sunshine Lake Pharma discovers sodium/glucose cotransporter 1 inhibitors

Aug. 16, 2019

Positive topline results presented from ELIPSE HoFH phase III study of evinacumab

Aug. 16, 2019

Xiangbei Welman Pharmaceutical describes compounds for gout, hyperuricemia

Aug. 13, 2019

PCOS linked to interleukin-22 by way of microbiome

Aug. 12, 2019

NIH awards major grant to ImmunogenX to conduct phase II study for latiglutenase

Aug. 9, 2019

Mapping microbial metabolites to GPCRs

Aug. 9, 2019

Applied Therapeutics reports data from SAD portion of phase I/II study of AT-007

Aug. 8, 2019

Phase III data announced for setmelanotide in POMC and LEPR deficiency obesities

Aug. 8, 2019

New metabolic syndrome target

Aug. 8, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Other news to note for May 1, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: AC Immune, Aptose, Astrazeneca, Bioreference Health, Cardioline,...